Clinical Trials
411 trialsNCT03460977 2026-06-05
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT06095505 2026-06-05
ALISCA-Lung1
Puma Biotechnology, Inc.
Phase 2 Recruiting
NCT06257264 2026-06-05
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT04458259 2026-06-04
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT07005128 2026-06-04
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07226999 2026-06-04
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT07476287 2026-06-04
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Pfizer
Phase 2 Recruiting
NCT07488676 2026-06-04
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT07559019 2026-06-04
Safety and Preliminary Activity of BI115 in Advanced SCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Recruiting
NCT07625644 2026-06-04
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
SystImmune Inc.
Phase 3 Not yet recruiting
NCT07623369 2026-06-03
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
Phase 1 Not yet recruiting
NCT07623642 2026-06-03
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20 Therapeutics
Phase 2 Not yet recruiting
NCT06203210 2026-06-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT06936735 2026-06-02
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07046923 2026-06-02
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Recruiting
NCT07454642 2026-06-02
FOCUS-01
Avacta Life Sciences Ltd
Phase 1 Recruiting
NCT07472517 2026-06-02
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT04938817 2026-06-01
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05783622 2026-06-01
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
Phase 1 Active not recruiting
NCT06646276 2026-06-01
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06712355 2026-06-01
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT06598306 2026-05-29
DeLLphi-308
Amgen
Phase 1 Recruiting
NCT07531095 2026-05-29
DeLLphi-313
Amgen
Phase 1 Recruiting
NCT07559929 2026-05-29
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06077500 2026-05-27
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07099898 2026-05-27
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT07459634 2026-05-27
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT07564401 2026-05-27
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Novartis
Phase 1/2 Recruiting
NCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06612151 2026-05-26
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Active not recruiting
NCT07278479 2026-05-22
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Phase 1/2 Recruiting
NCT06898957 2026-05-20
(DeLLphi-310)
Amgen
Phase 1 Active not recruiting
NCT06992609 2026-05-20
ALBORAN
AstraZeneca
Phase 3 Recruiting
NCT06892548 2026-05-19
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
BioNTech SE
Phase 1/2 Recruiting
NCT07155174 2026-05-18
SEZanne
AbbVie
Phase 2 Recruiting
NCT07391670 2026-05-15
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT07218146 2026-05-14
DLLEVATE
Zai Lab (Hong Kong), Ltd.
Phase 3 Recruiting
NCT05153239 2026-05-13
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Phase 3 Completed
NCT06799286 2026-05-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT07038343 2026-05-13
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04429087 2026-05-12
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Boehringer Ingelheim
Phase 1 Recruiting
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT05363280 2026-05-08
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Advenchen Laboratories, LLC
Phase 2 Recruiting
NCT05963867 2026-05-08
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Boehringer Ingelheim
Phase 1 Recruiting
NCT07296809 2026-05-08
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05599984 2026-05-07
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT07325136 2026-05-07
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT04553133 2026-05-06
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT07006727 2026-05-05
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Novartis
Phase 1 Recruiting